Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis

Yang X, Deng H, Sun Y, Zhang Y, Lu Y, Xu G, Huang X

Journal of Hepatocellular Carcinoma 2023, 10:303-313

Published Date: 27 February 2023